Skip to content

Biomarker-Based Study for the Assessment and Prediction of Cognitive Recovery in Patients with Stroke

Biomarker-Based Study for the Assessment and Prediction of Cognitive Recovery in Patients with Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112275
Enrollment
Unknown
Registered
2025-11-12
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke cognitive impairment, PSCI

Interventions

Healthy Control Group:none
Stroke Group:None

Sponsors

Beijing Bo'ai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Stroke Group:; 1. Patients with acute stroke, medically confirmed by MRI/CT (complete imaging data available), admitted to the hospital at 4-6 weeks post-stroke onset; 2. All participants are right-handed; Healthy Control Group:; 1. Age- and gender-matched healthy volunteers, Completed Mini-Mental State Examination (MMSE) assessment, with an MMSE score >= 27 (adjusted for educational level where applicable); 2.All participants are right-handed;

Exclusion criteria

Exclusion criteria: Stroke Group: 1. Patients with aphasia , severe hearing or visual impairment; 2. Patients with pre-stroke decreased level of consciousness , or pre-existing cognitive impairment due to conditions such as infection, metabolic disorders, or neurodegenerative diseases (e.g., Alzheimer's disease, depression, etc.); 3. Patients severely ill post-stroke with impaired consciousness preventing cooperation with examinations; 4. Patients with dysfunction of major organs (e.g., heart, lung, liver), endocrine disorders, connective tissue diseases, or hematologic diseases; 5. Patients with a history of psychiatric illness or behavioral disorders . Healthy Control Group: 1. Individuals with a history of neurological or psychiatric disorders; 2.Individuals with diseases significantly affecting the cognitive system (e.g., unstable thyroid dysfunction without stabilized treatment , severe diabetes mellitus, etc.); 3.Having severe cardiovascular or respiratory diseases, or liver and kidney dysfunction, malignant tumors, etc; 4. Individuals who are pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Assessments using the cognitive function scale ;Levels of serum BDNF, P-Tau181, NfL, and PGP9.5 (UCH-L1) ;Patient demographic data(age, sex/gender, BMI, education level, lifestyle history (history of smoking, history of alcohol consumption), and underlying diseases);Clinical and admission imaging findings for the patient;Length of hospital stay for rehabilitation treatment.;

Countries

China

Contacts

Public ContactWen Xing

Beijing Bo'ai Hospital

xingwenpumc@126.com+86 10 8756 9187

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026